SCHEMBL906132

SCHEMBL906132

c1ccc(COc2nccc(N3CCNCC3)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 3/20 0.53
▸ SLC6A2 P23975 3/20 0.53
▸ SLC6A3 Q01959 3/20 0.53
▸ SLC6A4 P31645 2/20 0.53
▸ PRMT5 O14744 1/20 0.52
▸ HRH3 Q9Y5N1 1/20 0.51
▸ HTR6 P50406 4/20 0.48
▸ PLD1 Q13393 1/20 0.48
▸ ACHE P22303 1/20 0.47
▸ NTRK1 P04629 1/20 0.47
▸ CYP1A2 P05177 2/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ HRH4 Q9H3N8 3/20 0.46
▸ PIM1 P11309 1/20 0.45
▸ PIM3 Q86V86 1/20 0.45
▸ PIM2 Q9P1W9 1/20 0.45
▸ TAAR1 Q96RJ0 1/20 0.45
▸ HTR2C P28335 3/20 0.45
▸ HTR2A P28223 2/20 0.45
▸ HTR2B P41595 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL905954 0.91 KDM4E (0.51) HTR1ASLC6A2SLC6A3SLC6A4PRMT5
SCHEMBL5585318 0.87 HTR2A (0.45) HTR1ASLC6A2SLC6A3SLC6A4PRMT5
SCHEMBL5585635 0.86 HTR3A (0.48) HTR1ASLC6A2SLC6A3SLC6A4PRMT5
SCHEMBL906027 0.85 HTR2C (0.64) HTR1AHTR6HTR2CHTR2AHTR2B
SCHEMBL906110 0.85 PRMT5 (0.56) HTR1ASLC6A2SLC6A4PRMT5HRH3
SCHEMBL906199 0.84 HTR6 (0.51) HTR1ASLC6A2SLC6A4PRMT5HRH3
SCHEMBL905817 0.84 NMT1 (0.56) HTR1ASLC6A4HRH3HTR6PLD1
SCHEMBL905754 0.83 HTR2C (0.50) HTR1AHRH3HTR6CYP1A2HRH4
SCHEMBL905995 0.83 HRH3 (0.48) HTR1APRMT5HRH3HTR6CYP1A2
SCHEMBL5585277 0.82 ADRB1 (0.54) HTR1ASLC6A4PRMT5HRH3HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050054656-A1 5-HT receptor ligands and uses thereof PFIZER INC 2005-03-10 — — US claimed
EP-1401819-A1 5-HT RECEPTOR LIGANDS AND USES THEREOF Pfizer Products Inc. (US) 2004-03-31 — — EP claimed
US-20030105106-A1 5-HT receptor ligands and uses thereof CHIANG PHOEBE (US) 2003-06-05 — — US claimed
WO-2003000663-A1 5-HT RECEPTOR LIGANDS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2003-01-03 — — WO claimed
US-20110152272-A1 Treatment Of Incontinence PFIZER INC 2011-06-23 — — US disclosed
EP-2277513-A2 Treatment of incontinence with 5htc2 agonists Pfizer Inc. (US) 2011-01-26 — — EP disclosed
US-20080146583-A1 Treatment of Incontinence PFIZER INC 2008-06-19 — — US disclosed
US-6995159-B2 5-HT receptor ligands and uses thereof PFIZER INC. (US) 2006-02-07 — — US disclosed
EP-1620081-A2 TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS Pfizer Limited (GB) 2006-02-01 — — EP disclosed
US-20050054656-A1 5-HT receptor ligands and uses thereof PFIZER INC 2005-03-10 — — US disclosed
US-20050032809-A1 5-HT receptor ligands and uses thereof PFIZER INC 2005-02-10 — — US disclosed
US-6825198-B2 FOR THERAPY OF SEXUAL DISORDER PFIZER INC 2004-11-30 — — US disclosed
US-20040235856-A1 Treatment of incontinence PFIZER INC 2004-11-25 — — US disclosed
WO-2004096196-A2 TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS PFIZER LIMITED (GB) 2004-11-11 — — WO disclosed
EP-1401819-A1 5-HT RECEPTOR LIGANDS AND USES THEREOF Pfizer Products Inc. (US) 2004-03-31 — — EP disclosed
US-20030105106-A1 5-HT receptor ligands and uses thereof CHIANG PHOEBE (US) 2003-06-05 — — US disclosed
WO-2003000663-A1 5-HT RECEPTOR LIGANDS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2003-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032809-A1 5-HT receptor ligands and uses thereof HTR2A, HTR1A, HTR5A HTR1A 2/4885SLC6A2 67/4885SLC6A3 173/4885
US-20040235856-A1 Treatment of incontinence HTR2C, HTR5A, ADRA2C HTR1A 15/4885SLC6A2 36/4885SLC6A3 122/4885
US-20030105106-A1 5-HT receptor ligands and uses thereof HTR1A, HTR2A, HTR5A HTR1A 1/4885SLC6A2 74/4885SLC6A3 175/4885
US-20110152272-A1 Treatment Of Incontinence HTR2C, HTR5A, ADRA2C HTR1A 15/4885SLC6A2 36/4885SLC6A3 122/4885
US-20080146583-A1 Treatment of Incontinence HTR2C, HTR5A, ADRA2C HTR1A 15/4885SLC6A2 36/4885SLC6A3 122/4885
US-20050054656-A1 5-HT receptor ligands and uses thereof HTR2A, HTR1A, HTR5A HTR1A 2/4885SLC6A2 67/4885SLC6A3 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback